Xeris’ GVOKE (glucagon) Receives FDA’s Approval as The First Ready-To-Use Stable Liquid Glucagon for Severe Hypoglycemia

Xeris’ GVOKE (glucagon) Receives FDA’s Approval as The First Ready-To-Use Stable Liquid Glucagon for Severe Hypoglycemia Xeris’ GVOKE (glucagon) Receives FDA’s Approval as The First Ready-To-Use Stable Liquid Glucagon for Severe Hypoglycemia

Shots:

  •  The approval is based on three P-III studies (NCT02656069, NCT03091673, NCT03439072) assessing GVOKE vs conventional glucagon emergency kits in adults and children aged ≥2yrs. with T1D
  • The studies demonstrated 100% treatment success in children & 99% in adults. Usability research assessing GVOKE PFS and GVOKE HypoPen resulted in ~100% success rate in administering a full dose of glucagon utilizing 2-step administration process
  • GVOKE is the first premixed, prefilled, premeasured liquid glucagon administered via prefilled syringe (GVOKE PFS) or auto-injector (GVOKE HypoPen) in patients with severe hypoglycemic events and will be available in 0.5 mg/0.1 mL dose and a 1 mg/0.2 mL dose for pediatric and adolescent/adult patients respectively

Click here to­ read full press release/ article | Ref: Xeris Pharmaceutical | Image: Xeris Pharmaceutical